Development of novel immunotherapeutic approaches for the treatment of Epstein-Barr virus-associated malignancies.

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/1084043

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

Epstein-Barr virus (EBV) is attributed to cause 200,000 cancer cases annually. Malignancies associated with EBV include nasopharyngeal carcinoma and Hodgkins lymphoma. These malignancies have been treated, with limited success, by “adoptive immunotherapy” in which the patients T cells are expanded in the laboratory by stimulation with this virus, and infused back into the patient. This project aims to assess three novel approaches to enhance this form of treatment for therapeutic consideration.

Funded Activity Details

Start Date: 01-01-2015

End Date: 01-01-2017

Funding Scheme: Project Grants

Funding Amount: $378,940.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Applied Immunology (incl. Antibody Engineering, Xenotransplantation and T-cell Therapies)

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

Epstein-Barr virus (EBV) | T cell immunotherapy | T cell receptor | biomedical engineering | cancer immunotherapy

Related Links